Back to Rare Disease
NCT06714370
NCT06714370
Who may be able to join
Who might be able to join this trial:
- You are 18 years of age or older
- You have been diagnosed with primary central nervous system lymphoma (a type of cancer affecting the brain or spinal cord) that has come back or stopped responding to treatment, and you have recently started receiving a specific medication called tirabrutinib through national health insurance coverage between June 1, 2024 and June 30, 2025
- You are willing and able to give written consent to participate, or a legal representative can give consent on your behalf if you are unable to do so yourself
- In some cases, deceased patients may be included under a special approval that waives the usual consent requirement (confirm with trial site)
Who may not be able to join:
- Your cancer has not been confirmed through a tissue sample (biopsy) to be a specific type called large B-cell primary central nervous system lymphoma
- You have not previously received at least 2 cycles of a specific chemotherapy treatment called high-dose methotrexate
- You have HIV infection
- Your diagnosis is a specific type of cancer called Burkitt lymphoma
- You were already receiving other chemotherapy drugs or targeted antibody treatments at the time you started taking tirabrutinib
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial details
Status
Completed
Phase
Not Applicable
Sponsor
Ono Pharmaceutical Co., Ltd.
Registry
clinicaltrials_gov
Start date
3 February 2025
Est. completion
31 March 2026
Where this trial is recruiting
🇹🇼 Taiwan
Primary endpoints
Objective response rate (ORR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.